Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Depreciation & Amortization (CF): 2016-2025

Historic Depreciation & Amortization (CF) for Rocket Pharmaceuticals (RCKT) over the last 10 years, with Sep 2025 value amounting to $2.7 million.

  • Rocket Pharmaceuticals' Depreciation & Amortization (CF) rose 45.98% to $2.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.0 million, marking a year-over-year increase of 32.67%. This contributed to the annual value of $7.2 million for FY2024, which is 46.06% up from last year.
  • Latest data reveals that Rocket Pharmaceuticals reported Depreciation & Amortization (CF) of $2.7 million as of Q3 2025, which was up 32.45% from $2.0 million recorded in Q2 2025.
  • Over the past 5 years, Rocket Pharmaceuticals' Depreciation & Amortization (CF) peaked at $2.7 million during Q3 2025, and registered a low of $700,000 during Q1 2021.
  • Over the past 3 years, Rocket Pharmaceuticals' median Depreciation & Amortization (CF) value was $1.8 million (recorded in 2024), while the average stood at $1.8 million.
  • Data for Rocket Pharmaceuticals' Depreciation & Amortization (CF) shows a peak YoY soared of 600.00% (in 2021) over the last 5 years.
  • Quarterly analysis of 5 years shows Rocket Pharmaceuticals' Depreciation & Amortization (CF) stood at $1.0 million in 2021, then skyrocketed by 37.50% to $1.1 million in 2022, then rose by 11.00% to $1.4 million in 2023, then surged by 30.52% to $1.8 million in 2024, then skyrocketed by 45.98% to $2.7 million in 2025.
  • Its Depreciation & Amortization (CF) stands at $2.7 million for Q3 2025, versus $2.0 million for Q2 2025 and $2.5 million for Q1 2025.